CatalystWireBeta

UK small-cap RNS · 27 Oct 2025

Every announcement of UK small & mid caps under £2bn. The ones that started or moved a situation are marked – a click opens it.

Sort: Newest · Largest companies
  1. 10:16
    Energean ENOG £1,358m
    9-Months 2025 Production and Adjusted EBITDAX
    Nine-month output of 151 kboed sits within the 145-155 kboed full-year guidance, so guidance is confirmed rather than changed. Q3 output rebounded strongly, but EBITDAX is lower year-on-year.
    Upgrade / downgrade cycle in line −0.5% on the day
    Moved: new: Israel production disruptions – Output recovered in Q3 after June suspension
  2. 07:33
    Half-year Results Results
    Unaudited interims for an early-stage explorer; no financial figures given in the text, the story is permit progress at Hussar (Environmental plan approved, final drill approval awaited) and funding via the August placing.
    Project milestones £1.0m · 4% of mcapoutlook positive +0.0% on the day
    Moved: Relist the enlarged company on the London Stock Exchange (first Q1 2024, later J: pending → delivered – The company was readmitted to the LSE main market on 30 July 2024 with a £5.0m raise. · Use the proceeds of placings to advance Hussar and Mt Winter work programmes: pending → on_track – Net proceeds of the August 2025 placing are earmarked for Hussar and Mt Winter work programmes and working capital. · Complete the 100% acquisition of Mt Winter and begin re-entry drilling by mid 20: pending → delayed – Mt Winter acquisition still awaits the draft ALRA agreement from the Central Land Council before the tenement is granted and settlement made.
  3. 07:00
    2025 Annual Accounts Timetable Update
    Annual accounts for the year to 31 March 2025 are still unpublished, with audit not finished and now expected in November 2025, so the reporting timetable has slipped further.
    Legal & regulatory first since Oct 2023 +0.0% on the day
    Moved: new: Delayed 2025 annual accounts – Audit being finalised; results expected in November 2025
  4. 07:00
    3rd Quarter Results Results
    NAV per share rose 7.9% q-o-q to GEL 135.51, driven by private portfolio operating gains and the Lion Finance Group (LFG) share price, with buybacks adding to it. A one-off Imedi L litigation reserve took off 1.0 ppt.
    Capital return outlook positive +1.0% on the day
    Moved: new: GEL 700m capital return programme – Launched Aug 2025; US$ 26.3m bought back · new: Gormed hospital acquisition – Agreed 25 Oct 2025, pending regulatory approval · new: Imedi L legacy litigation – Appeal rejected; fully provided in 3Q25
  5. 07:00
    Trading Update Trading update
    Board expects FY April 2026 trading profit before tax above £71m, double the £35.5m prior year, backed by matching cash flow improvement; first guidance from a company that normally gives none.
    Disposal of a part (break-up) £71.0m · 7% of mcapoutlook positive, raisedfirst since Oct 2023 +32.7% on the day
    Moved: new: Special interim dividend – Declared; ex-dividend 6 November 2025 · new: FY2026 profit guidance – Guidance given, first ever
  6. 07:00
    Final Audited Results Results
    Pre-revenue developer: loss narrowed to £2.93m from £3.90m and cash rose to £6.37m after the raise, but still no production and permitting milestones remain ahead.
    Project milestones £10.1m · 14% of mcapoutlook positivefirst since Oct 2023 +0.0% on the day
    Moved: new: Taronga permitting and development approval – EIS submitted September 2025 · new: Tellerhäuser fast-track permitting – LoMP submission being progressed
  7. 07:00
    Final Results Results
    Prelim FY2025 results show technical progress (MREP above 55% TREO) and strong backing, but the Phalaborwa DFS is now later than originally planned, pushing construction to 2027.
    Project milestones outlook positivefirst since Oct 2023 −13.2% on the day
    Moved: new: Phalaborwa DFS and financing – DFS delayed to 2026; construction targeted 2027 · new: Uberaba Economic Assessment – Economic Assessment underway · new: Phalaborwa separation route evaluation – Evaluation underway
  8. 07:00
    Trading Update Trading update
    H1 growth is strong across KPIs, but FY26 revenue and underlying EBITDA are only said to be on track with market expectations (£29.6m / £2.3m). Guidance is confirmed, not raised.
    Project milestones in lineoutlook positivefirst since Oct 2023 +6.8% on the day
    Moved: new: New-build surgical hub – Planning approved; discharging environmental conditions

Share this quote

Quote card
Post on X WhatsApp Download image

The link opens this announcement with the quote highlighted. Quotes are checked against the original text.

Add a note